BioMarin Pharmaceutical | BMRN - Selling And Administration Expenses


BioMarin Pharmaceutical reported $258.28M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
Insmed USD 247.26M 34.78M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Moderna USD 173M 135M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026